World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders

TY - JOUR

T1 - World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders

AU - WFSBP Task Force On Eating Disorders

AU - Himmerich, Hubertus

AU - Lewis, Yael Doreen

AU - Conti, Chiara

AU - Mutwalli, Hiba

AU - Karwautz, Andreas

AU - Sjögren, Jan Magnus

AU - Uribe Isaza, María Mercedes

AU - Tyszkiewicz-Nwafor, Marta

AU - Aigner, Martin

AU - McElroy, Susan L

AU - Treasure, Janet

AU - Kasper, Siegfried

N1 - Funding Information: Hubertus Himmerich has received salary support from the National Institute of Health Research (NIHR) Mental Health Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust (SLaM) and King’s College London (KCL) and a research grant from the NIHR Health Technology Assessment (HTA) Programme to test the feasibility of an RCT on olanzapine in AN. He has been a consultant for COMPASS Pathfinder Ltd, and he is the chief investigator of a proof-of-concept study testing psilocybin in AN which is an industry cooperation between SLaM, COMPASS Pathfinder Limited, and Worldwide Clinical Trials Limited. Hiba Mutwalli has received a sponsorship from the Saudi Arabian government for higher education. Andreas Karwautz has received salary support from the Medical University of Vienna, has not got any honoraria during the past 5 years from pharmaceutical industry producing medications mentioned in the guideline. He is vice-president of the scientific network society ‘Therapeutic Drug Monitoring in Child and Adolescent Psychiatry, e.V.’ based in Würzburg, Germany, and vice-president of the ‘Austrian Society on Eating Disorders’, Susan L. McElroy has been a consultant to or member of the scientific advisory boards of Allergan, Avanir, Bracket, F. Hoffmann-La Roche Ltd. Idorsia, Mitsubishi Tanabe Pharma America, Myriad, Novo Nordisk, Opiant, Otsuka, Sipnose, Sunovion, and Takeda. She has been a principal or co-investigator on studies sponsored by Allergan, Avanir, Brainsway, Idorsia, Janssen, Marriott Foundation, Medibio, Myriad, National Institute of Mental Health, Neurocrine, Novo Nordisk, Otsuka, and Sunovion. She is also an inventor on United States Patent No. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and along with the patent’s assignee, University of Cincinnati, Cincinnati, Ohio, has received payments from Johnson & Johnson, which has exclusive rights under the patent. Janet Treasure has received salary support from the National Institute of Health Research (NIHR) Mental Health Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust (SLaM) and King’s College London (KCL). Siegfried Kasper received grants/research support, consulting fees, and/or honoraria within the last three years from Angelini, AOP Orphan Pharmaceuticals AG, Celgene GmbH, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sage, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., and Takeda. Fernando Fernandez-Aranda received consultancy honoraria from Novo Nordisk and editorial honoraria as EIC from Wiley. Yael Doreen Lewis, Chiara Conti, Jan Magnus Sjögren, María Mercedes Uribe Isaza, Marta Tyszkiewicz-Nwafor, and Martin Aigner declare no conflicts of interest. Publisher Copyright: © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

PY - 2023

Y1 - 2023

N2 - OBJECTIVES: This 2023 update of the WFSBP guidelines for the pharmacological treatment of eating disorders (EDs) reflects the latest diagnostic and psychopharmacological progress and the improved WFSBP recommendations for the assessment of the level of evidence (LoE) and the grade of recommendation (GoR).METHODS: The WFSBP Task Force EDs reviewed the relevant literature and provided a timely grading of the LoE and the GoR.RESULTS: In anorexia nervosa (AN), only a limited recommendation (LoE: A; GoR: 2) for olanzapine can be given, because the available evidence is restricted to weight gain, and its effect on psychopathology is less clear. In bulimia nervosa (BN), the current literature prompts a recommendation for fluoxetine (LoE: A; GoR: 1) or topiramate (LoE: A; GoR: 1). In binge-eating disorder (BED), lisdexamfetamine (LDX; LoE: A; GoR: 1) or topiramate (LoE: A; GoR: 1) can be recommended. There is only sparse evidence for the drug treatment of avoidant restrictive food intake disorder (ARFID), pica, and rumination disorder (RD).CONCLUSION: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.

AB - OBJECTIVES: This 2023 update of the WFSBP guidelines for the pharmacological treatment of eating disorders (EDs) reflects the latest diagnostic and psychopharmacological progress and the improved WFSBP recommendations for the assessment of the level of evidence (LoE) and the grade of recommendation (GoR).METHODS: The WFSBP Task Force EDs reviewed the relevant literature and provided a timely grading of the LoE and the GoR.RESULTS: In anorexia nervosa (AN), only a limited recommendation (LoE: A; GoR: 2) for olanzapine can be given, because the available evidence is restricted to weight gain, and its effect on psychopathology is less clear. In bulimia nervosa (BN), the current literature prompts a recommendation for fluoxetine (LoE: A; GoR: 1) or topiramate (LoE: A; GoR: 1). In binge-eating disorder (BED), lisdexamfetamine (LDX; LoE: A; GoR: 1) or topiramate (LoE: A; GoR: 1) can be recommended. There is only sparse evidence for the drug treatment of avoidant restrictive food intake disorder (ARFID), pica, and rumination disorder (RD).CONCLUSION: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.

UR - http://www.scopus.com/inward/record.url?scp=85153759135&partnerID=8YFLogxK

U2 - 10.1080/15622975.2023.2179663

DO - 10.1080/15622975.2023.2179663

M3 - Review article

C2 - 37350265

SN - 1562-2975

VL - 24

SP - 643

EP - 706

JO - The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry

JF - The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry

IS - 8

ER -